Holen Sie sich die Stockscreener-App
3.365
0.15%
-0.005
Handel nachbörslich:
3.37
0.005
+0.15%
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Exit strategy if you’re trapped in Arbutus Biopharma CorporationPortfolio Update Report & Stepwise Trade Signal Guides - Newser
Volatility clustering patterns for Arbutus Biopharma CorporationQuarterly Trade Summary & Low Drawdown Trading Strategies - Newser
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Real time scanner hits for Arbutus Biopharma Corporation explainedJuly 2025 Review & High Conviction Investment Ideas - Newser
Chardan Capital Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Understanding Arbutus Biopharma Corporation’s price movementJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - Newser
XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation stock outlook for YEARWeekly Growth Portfolio Performance Summary - Newser
Forecasting Arbutus Biopharma Corporation price range with options dataStrong Buy Opportunity with Volume Support - Newser
Is Arbutus Biopharma Corporation stock ready for a breakoutStrategy Playbook for Risk Controlled Trades - Newser
Is Arbutus Biopharma Corporation stock reversal real or fakeBuy/Sell Zone Confirmation Technical Analysis - Newser
News impact scoring models applied to Arbutus Biopharma CorporationMomentum-Based Prediction for Quick Returns - Newser
Arbutus Biopharma Corporation stock momentum explainedTrading Watchlist with Real Time Filters - Newser
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
How to integrate Arbutus Biopharma Corporation into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
What moving averages say about Arbutus Biopharma CorporationFree Smart Money Tracking Signal Generator - Newser
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Position Decreased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Applying big data sentiment scoring on Arbutus Biopharma CorporationTechnical Safety Zone Pattern Recognition - Newser
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Wall Street Zen - Defense World
Is now a turning point for Arbutus Biopharma CorporationFree Alpha Focused Technical Trade Signals - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryFree Community Strategy With High Win Rate - Newser
When is the best time to buy Arbutus Biopharma Corporation stockPortfolio Safety Metrics and Return Analysis - Newser
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug - MyChesCo
What risks could impact Arbutus Biopharma Corporation stock performanceLong Term Stock Growth Plan Suggestions - Newser
Arbutus: Q2 Earnings Snapshot - Connecticut Post
Arbutus Biopharma Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Arbutus Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
Arbutus Biopharma Reports Q2 Earnings of $2.523mln, Revenue of $10.739mln, EPS of $0.01 - AInvest
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 an - GuruFocus
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Real time social sentiment graph for Arbutus Biopharma CorporationHigh Return Strategy with Low Risk - Newser
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma Corporation stock trendline breakdownMarket Timing Strategy with Technical Filters - Newser
What are the latest earnings results for Arbutus Biopharma CorporationBuild a diversified portfolio for steady growth - Jammu Links News
What are the technical indicators suggesting about Arbutus Biopharma CorporationTriple-digit returns - Jammu Links News
What data driven models say about Arbutus Biopharma Corporation’s futureShort Term High Yield Stock Tips for Active Traders - beatles.ru
Bank of New York Mellon Corp Decreases Holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Technical analysis overview for Arbutus Biopharma Corporation stockFree Buy Low Sell High Stock Watch - Newser
Arbutus Biopharma Corporation Recovery Hinges on Volume BreakoutSecure Return Focused Investment Plan Released - metal.it
Published on: 2025-07-30 00:59:28 - Newser
Will breakout in Arbutus Biopharma Corporation lead to full recoveryFree Reliable Chart-Based Trade Entries - Newser
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):